Metastatic glioma represents a rare but serious situation where aggressive brain tumors spread beyond their original location. Though standard treatments exist to slow disease progression and manage symptoms, new research approaches continue to explore better ways to help patients live longer and with improved quality of life.

Understanding Treatment Goals for Advanced Brain Tumors

When a glioma spreads beyond its original site in the brain or extends outside the central nervous system, treatment becomes more complex. The main goals shift toward controlling tumor growth, reducing pressure on healthy brain tissue, and improving daily functioning. While complete cure remains challenging, especially for high-grade metastatic gliomas, medical teams work to extend survival time and maintain the best possible quality of life for patients.

Treatment plans are highly individualized, taking into account the specific type of glioma, where it has spread, how aggressive it is, and the patient’s overall health condition. Some patients remain able to continue daily activities like work or caring for family, though extra planning and support become necessary. The treatment journey typically involves multiple medical specialists working together, including neurosurgeons, radiation oncologists, and neuro-oncologists, all coordinating to provide comprehensive care.^[1][5]

Standard treatments approved by medical societies form the foundation of care, but research into novel therapies continues through clinical trials. These trials test innovative approaches that may eventually become new standard options. Understanding both established treatments and emerging possibilities helps patients and families make informed decisions about their care path.

Standard Treatment Approaches

The cornerstone of glioma treatment begins with surgery whenever safely possible. Surgical resection—the removal of the tumor or as much of it as can be taken out without damaging vital brain tissue—serves multiple purposes. It reduces pressure inside the skull, removes cancerous cells, and provides tissue samples for detailed analysis. Sometimes complete removal isn’t feasible because the tumor has grown into areas controlling critical functions like speech, movement, or memory. In these cases, surgeons remove what they can while preserving quality of life.^[7][11]

Following surgery, most patients receive radiation therapy. This treatment uses focused beams of energy to kill remaining cancer cells that couldn’t be removed surgically. Radiation oncologists carefully plan the treatment to target tumor cells while minimizing damage to surrounding healthy brain tissue. The standard course typically involves daily sessions over several weeks. Advanced techniques allow doctors to shape the radiation beam precisely to match the tumor’s contours, improving effectiveness while reducing side effects.^[7]

Chemotherapy forms the third pillar of standard care. Temozolomide is the most commonly used chemotherapy drug for malignant gliomas. Patients take this medication orally, usually in pill form, making it more convenient than intravenous chemotherapy. Temozolomide works by damaging the DNA inside cancer cells, preventing them from multiplying. The drug has been used for over twenty years and has a relatively manageable side effect profile compared to many other chemotherapy agents. Common side effects include nausea, fatigue, and temporary reduction in blood cell counts, requiring regular monitoring through blood tests.^[7][14]

The duration of chemotherapy varies depending on how the tumor responds and how well the patient tolerates treatment. Some patients continue chemotherapy for many months, while others may need to adjust or stop if side effects become too severe. During treatment, medical teams monitor patients closely through regular brain scans, typically using magnetic resonance imaging (MRI), which creates detailed pictures of the brain without using radiation. These scans help doctors see whether the tumor is shrinking, staying stable, or growing despite treatment.^[7]

Another treatment option, called tumor treating fields (TTFields), became available several years ago for glioblastoma, the most aggressive type of glioma. This approach uses electrical fields to disrupt cancer cell division. Patients wear a device on their head that delivers these fields continuously. While it doesn’t work for everyone, some patients have lived longer when combining TTFields with standard chemotherapy. The main drawback is the need to wear the device most of the day, which some patients find burdensome.^[14]

When gliomas spread outside the brain—an extremely rare occurrence—treatment becomes even more challenging. The most common sites for extracranial spread include the spine, bones, lungs, liver, and lymph nodes. Doctors typically use combinations of surgery (when possible), radiation to metastatic sites, and systemic chemotherapy that can reach cancer cells throughout the body. Unfortunately, outcomes remain poor, with most patients surviving less than six months after extracranial metastases are discovered.^[2][8]

Emerging Treatments in Clinical Trials

Clinical trials represent the frontier of glioma treatment, testing new approaches that might eventually become standard care. These studies progress through phases: Phase I focuses on safety and determining the right dose, Phase II examines whether the treatment actually works against the cancer, and Phase III compares the new treatment directly to current standards.^[13]

One of the most promising areas of research involves immunotherapy—treatments that harness the patient’s own immune system to fight cancer. While immunotherapy has transformed treatment for cancers like melanoma and lung cancer, brain tumors have proven more resistant. The brain’s unique biology makes it harder for immune cells to reach tumors, and glioblastomas create an environment that suppresses immune responses. Despite these challenges, researchers continue developing new immunotherapy strategies specifically designed for brain tumors.^[14]

CAR T-cell therapy represents one of the most exciting immunotherapy approaches under investigation. This treatment involves removing a patient’s own T cells (a type of immune cell), genetically modifying them in the laboratory to recognize and attack glioblastoma cells, then infusing them back into the patient. Scientists design these modified cells to target specific proteins on tumor cells, such as EGFRvIII, a mutated protein found in some glioblastomas. Early studies have shown encouraging results in certain patient subgroups, though the therapy remains in early development stages. CAR T-cell therapy is already approved for some blood cancers, giving hope that similar success might eventually be achieved for brain tumors.^[14]

Researchers are also exploring targeted therapies—drugs designed to attack specific molecular abnormalities in cancer cells. Recent advances in understanding glioma genetics have revealed that these tumors harbor various mutations and genetic changes. Some gliomas have mutations in genes called IDH (isocitrate dehydrogenase). These mutations change how cancer cells metabolize nutrients and produce energy. Scientists have developed drugs specifically targeting these mutated enzymes, and clinical trials are testing whether blocking them can slow tumor growth or even shrink tumors.^[12]

The GBM AGILE trial represents an innovative approach to testing multiple new treatments simultaneously. This platform study allows researchers to evaluate several different experimental drugs at once, comparing each to standard treatment. The trial includes extensive biobanking—collecting and storing tumor samples and other biological materials from participants. This resource helps scientists identify which patients are most likely to benefit from specific treatments based on their tumor’s molecular characteristics. The approach mirrors successful strategies used in lung cancer research, where understanding tumor genetics led to dramatic improvements in treatment outcomes.^[14]

Clinical trials for metastatic glioma may be conducted at specialized cancer centers across the United States, Europe, and other regions. Eligibility criteria vary by trial but typically consider factors like the patient’s age, overall health, prior treatments received, and specific characteristics of the tumor. Patients interested in clinical trials should discuss options with their neuro-oncologist, who can help determine which trials might be appropriate and assist with enrollment.^[13]

Some trials focus specifically on recurrent gliomas—tumors that return after initial treatment. Since most high-grade gliomas eventually recur despite treatment, developing effective therapies for recurrence remains a critical research priority. Investigational approaches for recurrent disease include new chemotherapy drugs, combinations of existing drugs in novel sequences, targeted radiation techniques, and various immunotherapy strategies.^[13]

Most common treatment methods

• Surgery (Surgical Resection)
  • Removal of as much tumor as safely possible, either total or partial resection
  • Helps reduce pressure in the brain, stop progression, and relieve symptoms
  • Provides tissue samples for detailed molecular analysis
  • May be performed with patient awake if tumor is near critical brain areas
• Radiation Therapy
  • Uses focused energy beams to destroy remaining cancer cells after surgery
  • Typically delivered in daily sessions over several weeks
  • Advanced techniques allow precise targeting of tumor while protecting healthy tissue
  • May be used for metastatic sites outside the brain when extracranial spread occurs
• Chemotherapy
  • Temozolomide is the standard chemotherapy drug taken orally in pill form
  • Works by damaging DNA in cancer cells to prevent multiplication
  • Used for over 20 years with relatively manageable side effects
  • Duration varies based on tumor response and patient tolerance
  • Requires regular blood monitoring for potential effects on blood cell counts
• Immunotherapy
  • CAR T-cell therapy being developed to use modified immune cells to attack tumors
  • Targets specific proteins on glioblastoma cells like EGFRvIII mutation
  • Still in early development stages for brain tumors
  • Early studies show promise in certain patient subgroups
  • Other immunotherapy approaches like checkpoint inhibitors have been less successful for gliomas
• Targeted Therapy
  • Drugs designed to attack specific molecular abnormalities in cancer cells
  • Targets mutations in genes like IDH (isocitrate dehydrogenase)
  • Works by blocking mutated enzymes that cancer cells depend on
  • Being tested in clinical trials for specific glioma subtypes
• Tumor Treating Fields (TTFields)
  • Uses electrical fields to disrupt cancer cell division
  • Patient wears device on head that delivers continuous treatment
  • Combined with chemotherapy for glioblastoma treatment
  • Has extended survival in some patients by several months

Managing Life with Metastatic Glioma

Living with metastatic glioma involves more than medical treatments. Patients often need support managing physical symptoms like headaches, seizures, weakness, or cognitive changes. Anti-seizure medications help control seizures, which occur in many glioma patients. Steroids like dexamethasone reduce brain swelling, though long-term use can cause side effects including weight gain, mood changes, and increased blood sugar.^[1]

Rehabilitation services play an important role in maintaining function and independence. Physical therapy helps with movement problems and weakness. Occupational therapy teaches strategies for managing daily activities despite limitations. Speech therapy addresses communication difficulties and swallowing problems. These services aim to preserve quality of life as much as possible throughout the treatment journey.^[20]

Follow-up care remains essential throughout and after treatment. Regular appointments include brain scans to monitor tumor status, neurological exams to assess function, and blood tests to check for treatment side effects. The frequency of these visits depends on disease status and treatment phase. Patients typically see their medical team more frequently during active treatment and less often during stable periods, though ongoing surveillance continues indefinitely.^[20]

Emotional and psychological support matters enormously. A brain tumor diagnosis brings fear, uncertainty, and often grief about losses—whether of abilities, independence, or future plans. Counseling services, support groups, and patient advocacy organizations provide valuable resources. Connecting with others facing similar challenges helps many patients and families cope with the emotional burden.^[18][21]